Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602471 · ClinicalTrials.gov registry record · Phase 2
[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis
A Phase 2 study, sponsored by Siemens Molecular Imaging.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01602471 is a Phase 2 study that was terminated before completion, run by Siemens Molecular Imaging. The registered enrollment target is 5 participants.
The verdict
NCT01602471, a Phase 2 study, was terminated before completion, sponsored by Siemens Molecular Imaging.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This trial will be the first trial for the Investigation Product (IP), \[F-18\]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase II imaging. All study results will be evaluated and analyzed in order to consider the design for future clinical trials.
Interventions
- DRUG [F-18]RDG-K5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602471
The ClinicalTrials.gov registry entry for NCT01602471 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Siemens Molecular Imaging, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [F-18]RDG-K5 is the first listed.
NCT01602471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602471 about?
NCT01602471 is a clinical study titled "[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis". This trial will be the first trial for the Investigation Product (IP), \[F-18\]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase II imaging. All study results will be evaluated and analyzed in order...
What is the current status of trial NCT01602471?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01602471?
The interventions under investigation include: [F-18]RDG-K5 (DRUG).
Who is sponsoring clinical trial NCT01602471?
This trial is sponsored by Siemens Molecular Imaging, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.